

Europäisches Patentamt
European Patent Office
Office européen des brevets

(11) Publication number:

0 179 483
A2

AH

(12)

EUROPEAN PATENT APPLICATION

(21) Application number: 85113585.5

(51) Int. Cl.⁴: C 12 P 21/00
//A61K39/42, G01N33/577

(22) Date of filing: 25.10.85

(30) Priority: 26.10.84 JP 226394/84

(72) Inventor: Eda, Yasuyuki
Yoshino-so 203 2-82, Shimizuhigashi-machi
Kumamoto-shi Kumamoto-ken(JP)

(43) Date of publication of application:
30.04.86 Bulletin 86/18

(72) Inventor: Maeda, Toshihiro
1909-1160, Kikutomi Koushi-machi
Kikuchi-gun Kumamoto-ken(JP)

(64) Designated Contracting States:
AT BE CH DE FR GB IT LI NL SE

(72) Inventor: Nishiyama, Kiyoto
Kei-Corpo 305, 923-1 Okubo, Shimizu-machi
Kumamoto-shi Kumamoto-ken(JP)

(71) Applicant: Juridical Foundation The
Chemo-Sero-Therapeutic Research Institute
668, Ohkubo Shimizu-machi
Kumamoto-shi Kumamoto-ken(JP)

(72) Inventor: Tashiro, Akira
244-5, Suya Nishigoushi-machi
Kikuchi-gun Kumamoto-ken(JP)

(54) Method for preparing monoclonal antibodies to HBsAg.

(74) Representative: Vossius Vossius Tauchner Heunemann
Rauh
Siebertstrasse 4 P.O. Box 86 07 67
D-8000 München 86(DE)

(57) Disclosed are monoclonal antibodies to the HBsAg which are prepared by forming hybridomas between human peripheral blood lymphocyte cells, derived from humans having high titers of anti-HBsAg antibodies, and myeloma cells, cloning the hybridomas and selecting the antibody-producing clones. The monoclonal antibodies react with all the subtypes of the HBsAg and are very effective in diagnosis and treatment of diseases due to the viral infection.

A2
EP 0 179 483 A2
L 100

Our Ref.: U 109 EP
Juridical Foundation the Chemo-
Sero-Therapeutic Research Institute

October 25, 1985

METHOD FOR PREPARING MONOCLONAL ANTIBODIES TO HBsAg

Background of the Invention

The present invention relates to monoclonal antibodies particularly, to human-derived monoclonal antibodies to the hepatitis B surface antigen (HBsAg).

Hepatitis B virus is a horrible infectious virus causing hepatic insufficiency and chronic hepatitis as well as acute hepatitis, which may develop to liver cirrhosis or liver cancer. Thus, early establishment of diagnosis and treatment of the diseases is being desired.

There are known three types of antibodies to hepatitis B virus: Antibodies to the virus surface antigen (HBsAg), antibodies to the virus core antigen (HBcAg) and antibodies to the antigen which is said to be contained within the core antigen(HBeAg). It has been recently confirmed that the antibodies to HBsAg possess neutralizing activity against hepatitis B virus and are now expected to serve as a reagent to prevent and treat the viral infection. Thus, medical preparations containing anti-HBsAg antibodies have attracted a good deal of attention, and attempts have been made to produce the preparations from human plasmas which are positive with respect to antibodies to HBsAg. However, such methods are disadvantageous in that there are limitations of supply of human plasmas as raw materials so that the preparations are expensive. An object of the

invention is to overcome and solve this problem.

Prior Art

It is known that the cell fusion technique makes it possible to produce homogeneous or monoclonal antibodies to certain viral antigens. For example, there is disclosed in Japanese Patent Publication No. 2276/1984 a method for preparing an anti-virus monoclonal antibody which comprises providing fused cell hybrids between anti-virus-antibody-producing cells found in spleens or lymph nodes in mice and myeloma cells, culturing the hybrids and collecting the antibody. However, the disclosed method is directed to antibodies to influenza virus or rabies virus. Further, the hybridomas disclosed in this patent application are mouse /mouse hybrid cells formed by fusing antibody-producing spleen cells from mice immunized with the virus antigen and BALB/c myeloma cells derived from the MOPC-21 line. Thus, the monoclonal antibodies produced are mouse-originated ones which give no guarantee whether they can be administered to humans without risks.

Japanese Laid-Open Patent Application No. 58718 /1981 discloses an anti-HBsAg monoclonal antibody, which is also produced from a hybridoma of mouse/mouse fused cells. There is left a doubt whether such antibody can be utilized to diagnose or treat hepatitis viral infections in humans.

In the Japanese Laid-Open Patent Application No. 72526/1983 the production of a human-based or human-derived monoclonal antibody against HBsAg is described. Human B lymphoid

cells are stimulated by immunization with HBs antigen which has been heated in the presence of a modifier such as urea or guanidine, and transformed to propagatable cells by Epstein-Barr Virus. However, in the patent application no definite disclosures are made as to the characteristics of the human-derived anti-HBsAg monoclonal antibody.

Summary of the Invention

After extensive studies to overcome the disadvantages of the conventional techniques, the present inventors have succeeded in producing and characterizing human-derived anti-HBsAg monoclonal antibodies (hereinafter also referred to as hHBs MCA's) which can be successfully utilized in diagnosis and treatment of hepatic diseases in humans. Thus, according to the present invention the hHBs MCA can be prepared stably and continuously by forming hybridomas by cell fusion of human peripheral blood lymphocyte cells, immunized with HBs antigen to a certain degree, and myeloma cells, cloning the hybridomas and selecting clones which produce antibodies to HBsAg.

The hHBs MCA's of the present invention cannot be contaminated with hepatitis B virus since they are derived from hybridomas. The hybridomas, if once established, can be stored for a long time under liquid nitrogen and can be utilized for the large-scale production of the hHBs MCA's by being propagated at any time when needed, without restriction by the supply of raw materials. The process for refining the MCA's is relatively simple, which

will also contribute to the less expensive production of the monoclonal antibodies (MCA's). The MCA's of the present invention are also characterized in that, in comparison with the anti-HBsAg antibodies obtained from plasma, they have an extremely higher specificity for the HBsAg. Moreover, the in vivo administration of the human-origin MCA of the invention in humans, does not cause side effects as the mouse/mouse anti-HBsAg monoclonal antibodies do.

The human-based MCA's and the method for their preparation according to the present invention will be described in more detail in the following.

Detailed Description of the Invention

For the production of an anti-HBsAg monoclonal antibody which is compatible to humans, the present invention is directed to the formation of hybridomas of fused mouse/human cells.

The human cells used are peripheral human blood lymphocyte cells derived from humans who are positive with respect to anti-HBsAg antibody. Specifically, it has been found by the present inventors that the humans for supplying the lymphocyte cells should have high anti-HBsAg antibody titers. Thus, such lymphocyte cells can be derived from humans who once had relatively high titers of anti-HBs antibodies, for example, at least 0.1 IU/ml) due to possible infections with hepatitis B virus and were then vaccinated with an HBs vaccine so that their titers of anti-HBsAg antibodies increased.

at least 10 IU/ml (preferably at least 100 IU/ml) in blood two to three weeks after the vaccination. Alternatively, the second selection may be carried out by collecting peripheral blood lymphocytes of humans after the administration of the HBs vaccine and then culturing these blood lymphocytes in vitro so that the culture supernatant contains anti-HBsAg antibody of at least 0.01 IU/ml (preferably at least 0.1 IU/ml). The peripheral blood lymphocyte cells collected two to three weeks after the vaccination are then cultured in vitro in the presence of a lymphocyte activating substance such as pokeweed mitogen (PWM). The use of peripheral blood lymphocyte cells derived from humans whose blood is anti-HBsAg-antibody negative before the vaccination or from humans who have the above-mentioned high antibody titers makes it extremely difficult to form mouse/human hybridomas which are capable of producing the desired hHBs MCA.

The human peripheral blood lymphocyte cells thus cultured are collected to be used for forming mouse/human hybridomas by being fused with a mouse myeloma cell line as X63-Ag8-6,5,3 or other cells derived from the MOPC-21 line. The cell fusion can be carried out in any known manner with a fusing agent exemplified by polyethyleneglycol. The selection of hybridomas is accomplished by cultivation in a suitable medium, particularly in HAT (hypoxanthine-aminopterin-thymidine) selective medium, for example, in RPM 1640 + 15 % fetal bovine serum + HAT medium supplemented with

glutamine, at 37 °C in the presence of 5 % CO₂. The hybridomas which will produce anti-HBsAg antibodies are identified e.g. by passive hemagglutination (PHA) using sheep red blood cells sensitized with HBs antigen, conventional antibody-determining methods for IgG or IgM, or by radioimmunoassay.

The mouse/human hybridomas which produce anti-HBsAg antibodies thus selected are subjected to limiting dilution for obtaining monoclones for the production of the human-based anti-HBsAg monoclonal antibodies. For establishing stable antibody-producing clones it is essential to repeatedly carry out the cloning operations at early stages.

The hHBs MCA-producing mouse/human hybridomas as established in the above-mentioned manner are then propagated in vitro or in an immunodeficient animal where the MCA to HBsAg is continuously produced. For example, the clones were intraperitoneally administered to pristane-primed BALB/c-derived nude mice.

Three to five weeks after the administration, the content of anti-HBsAg antibodies in the ascites was determined by RIA. Antibodies specific for the HBsAg were obtained from three of seven mice. Alternatively, the hybridoma cells can be propagated in vitro, particularly in a medium containing hypoxanthine-aminopterin-thymidine. Finally, the hHBs MCA's are recovered (refined) from the supernatants of

the cultures of the hybridoma cells or from the ascites fluid of the nude mice according to known methods as applied to recover immunoglobulins, for example, by conventional salting-out, DEAE-ion exchange chromatography, polyethyleneglycol-fractionation, gel filtration, or affinity chromatography with HBsAg-fixed beads.

If necessary, process steps may be carried out which are used in the production of immunoglobulins for intravenous injection, such as acid treatment, enzyme treatment, plasmin treatment, sulfonating treatment or polyethyleneglycol treatment. For the production of pharmaceutical preparations, the refined anti-HBsAg monoclonal antibodies can be subjected to known treatments as

concentration conditioning, addition of stabilizer(s), bacterial filtration and/or lyophilization.

The anti-HBsAg monoclonal antibodies produced by the mouse/human hybridoma according to the present invention are complete human IgG antibodies and not human/mouse chimeric antibodies. This was determined according to the immune precipitation method in which the monoclonal antibody of the present invention forms a precipitate with rabbit anti-human IgG antiserum but forms no precipitate with rabbit anti-mouse IgG antiserum. In addition the analysis by radioimmunoassay, which is more sensitive than immune precipitation, shows that the MCA's of

the present invention react with radioactively-labelled, rabbit anti-human IgG in proportion to the concentration of the antibody, but do not react

with radioactively- labelled rabbit anti-mouse IgG.

Furthermore, as a result of the PHA (passive hemagglutination)-inhibition test using sheep red blood cells sensitized with HBs antigen, it has been proved that the hHBs MCA's of the present invention are antibodies which recognize or identify the epitope "a", i.e. the antigenic determinant common to all the subclasses of HBs antigen. As is known, HBs antigen can be classified into four subclasses (adw, adr, ayw, and ayr) because of the presence of one common epitope (a) and two divided pairs of epitopes (d, y) and (w, r). The present invention is of great significance since it provides monoclonal antibodies being capable of recognizing the epitope (a) and hence reacting with all the types of hepatitis B surface antigen.

The hybridomas formed by the present invention, when cultured in vitro, are found to be able to produce the antibody specific for HBsAg in an amount of 7 µg/ml (7 µg/5 x 10⁵ cells/ml), where the antibody titer is 2¹² in terms of PHA or 50 IU (International Unit)/ml. These values demonstrate that the hybridomas are of a practical usefulness. It is also found that the hybridomas exhibit a doubling time of thirty hours and contains the fourteenth chromosome when determined by Q-band staining technique. The hybridomas of the present invention can be cultured without causing any substantial change, at least one year according to the finding by the inventors, to produce the hHBs MCA

continuously and stably.

Thus, the method of the present invention can be carried out in a relatively simple manner without need of complicated stages to prepare the hHBs MCA which has wide applications such as those in the diagnosis or the treatment of hepatic diseases or in the purification of HBs antigen.

The present invention is illustrated by the following example, which is not intended to limit the invention.

Examples

1. Preparation of immunizing antigen (vaccine):

Step 1: Anti-HBs antibody-positive human plasma was treated with calcium chloride and dextran sulfate, followed by salting-out of the supernatant with 1.2 M ammonium sulfate. After centrifugation, there was added to the supernatant with 1.8 M ammonium sulfate so as to precipitate the HBs antigen. Thus, there were removed about 80 % of the human plasma components and the plasma was concentrated about ten times.

Step 2: DEAE-Sephadex GL-6B gel (available from Pharmacia Co.) was sufficiently equilibrated with acetate buffer having ionic strength 0.05 and pH 5.5 and then packed within a column. After the HBs antigen-containing solution as obtained in Step 1 was subjected to dialysis with the above-mentioned buffer and the precipitate formed by dialysis was removed by centrifugation, the resultant solution was passed through the column. Thus, elution was

carried out in the manner of changing ionic strength stepwise with sodium chloride.

There was recovered 80 % of the HBs antigen in the passed-through fraction, in which primary serum protein was γ -globulin. The degree of purification was found to be fourteen times as compared with the starting material.

Step 3: CM-Sepharose CL-6B (available from Pharmacia Co.) gel was packed into a column after sufficient equilibration with acetate buffer having ionic strength 0.08 and pH 5.1. The passed-through fraction obtained in Step 2 was subjected to dialysis with the buffer and passed through the column. The elution operation was carried out stepwise with sodium chloride. There was recovered 24 to 48 % of the HBs antigen as the passed-through fraction, where the HBs antigen was found to have been further purified to 1,500 times as high as the starting material.

The final fraction contained the HBs antigen in terms of 1,024 as determined by γ -PHA. Analysis by Kjeldahl method showed that it contained proteins of 6 $\mu\text{g}/\text{ml}$. There were detected no serum components when the fraction, concentrated to 10 to 100 times, was analyzed by immuno-diffusion or immunoelectrophoresis. Examination of the serum proteins of rabbits, highly immunized with the refined HBs antigen, showed that there were four weak precipitation lines against NHS (normal human serum).

0179483

2. Selection of lymphocyte cells-supplying humans and immunization:

Selection is firstly made of humans who have high antibody titers of anti-HBs antigen (at least 0.1 IU/ml) in blood, by means of PHA or radioimmunoassay. Then, each of the selected humans is subcutaneously administered with 20 µg of the HBs vaccine as prepared in the above-mentioned manner and, about 2 weeks after the administration, there are selected humans who have titers of anti-HBs antigen of at least 10 IU/ml (most preferably at least 100 IU/ml) in blood. The second selection may also be carried out by selecting out humans whose peripheral blood lymphocyte cells are collected after the administration of the HBs vaccine and then cultured in vitro so that the culture supernatant contains a significant amount of anti-HBsAg antibody, i.e. at least 0.01 IU/ml, preferably at least 0.1 IU/ml.

3. Preparation of human peripheral blood

lymphocyte cells:

From peripheral blood collected at a predetermined time after the vaccine administration, peripheral blood lymphocyte cells were harvested by Ficoll-Hypaque gradient centrifugation of the peripheral blood. The lymphocyte cells were then suspended at 1×10^6 cells/ml in RPMI 1640 + 15 % bovine fetal serum added with glutamine followed by the addition of PWM at 2.5 the final concentration of µg/ml. Following culturing at 37 °C in the presence of CO₂ for 4 to 5 days, the production of anti-HBsAg antibody was detected in the culture supernatant. The lymphocyte cells were collected, washed twice with RPMI 1640 medium and then

-resuspended in the medium. The peripheral blood lymphocyte cells were obtained generally at a rate of about 4×10^7 cells from 40 ml of the peripheral blood, half of which (2×10^7 cells) were subjected directly to cell fusion with mouse myeloma cells to study the effects of the stimulation by PWM on the cell fusion as described later, with the remaining being supplied to cell fusion with the PWM stimulation.

4. Preparation of Myeloma cells:

The myeloma cell line used in the present invention was derived from mouse BALB/c myeloma as known from the disclosures in "Nature, 256, pp. 495 - 497 (1975)" or "Eur. g. Immunol., 6, pp. 292 - 295 (1976)" by Kohler et al, particularly X63-Ag8-6,5,3 or P3-X63-Ag8-U1. The myeloma cells were propagated in complete medium of RPMI 1640 + 15 % bovine fetal serum added with glutamine. The propagated cells were collected, washed twice with RPMI medium and then resuspended in the medium for use in the cell fusion.

5. Cell fusion between human peripheral blood lymphocyte cells and mouse myeloma cells:

The human lymphocyte cells suspension was mixed with the mouse myeloma cells suspension at a ratio of the human lymphocyte cells: the mouse myeloma cells = 1 : 2 and the mixture was centrifuged for 10 minutes at a rate of 1,500 rpm to form a pellet, to which was added, over one minute at 37 °C, 1 ml of 45 % polyethyleneglycol solution

(pH 7.6, molecular weight 3,650) diluted with RPMI. The resultant mixture, after being allowed to stand for five minutes, was added with 40 ml of RPMI 1640 and the cells were gently resuspended to terminate the fusion. Then the cells were subjected to centrifugation for 10 minutes at a rate of 1,000 rpm and resuspended in complete medium containing RPMI 1640 + 15 % bovine fetal serum added with glutamine to obtain fused cells at a human lymphocyte cell concentration of 5×10^5 cells/ml and at a myeloma cell concentration of 1×10^6 cells/ml. The resultant cells were plated in 96-well microtiter plates at a ration of 100 μ l per one well, followed by culturing at 37 °C in the presence of 5 % CO₂. After 24 hours, to each well was added 100 μ l of HAT selective medium (RPMI 1640 + 15 % bovine fetal serum + HAT added with glutamine). Further, at times of 24 hours and 48 hours later, 50 % of medium in each well was replaced with the HAT selective medium. Such 50 % medium replacements with the selective HAT medium were subsequently conducted every five days for two to three weeks until the hybridomas were sufficiently propagated for screening assay.

6. Screening assay and cloning of hybridomas:

For confirming sufficient propagation of the hybridomas, screening assay was carried out to detect clones producing the specific antibody: Firstly were screened the wells in which there was produced any antibody by means of radioimmunoassay (for determining human antibody), and then

there were screened, by means of radioimmunoassay for detecting anti-HBsAg antibody known as AUSAB[®] (Anti-HBsAg detecting kit available from Dinabot Co.), the wells in which there was produced antibody specific for HBsAg. The hybridomas in the wells thus screened were subjected to limiting dilution for cloning. At the time when the clones were propagated in the wells, the radioimmunoassay was effected to detect clones producing antibody specific for HBsAg. Such operations were repeatedly carried out as required to obtain stable mouse/human hybridomas. Depending upon necessities the hybridomas were propagated and stored in a frozen state under liquid nitrogen in freezing medium of HAT selective medium + 10 % DMSO (dimethylsulfoxide).

7. Effect of vaccine administration:

As shown in Table 1, the human peripheral blood lymphocyte cells for forming the hHBs MCA-producing hybridomas according to the present invention were derived from selected humans who had relatively high titers of anti-HBsAg (at least 0.1 IU/ml) in blood due to possible infections with hepatitis B virus in the past.

Such persons were then administered with the HBs vaccine and, two weeks after the vaccination, were determined for their antibody titers of anti-HBsAg. The results were also given in Table 1, demonstrating that hybridomas which effectively produce anti-HBsAg antibody were derived from humans who exhibited high titers in blood after the vaccine administration, i.e. at least about 10

IU/ml, most preferably at least about 100 IU/ml.

Table 1

Lympho- cyto Suppli- ers	Anti-HBsAg Titer before vaccine Administ- ration (IU/ml)	Anti-HBsAg Titer after vaccine Administ- ration (IU/ml)	Rate of Formation of anti-HBsAg Producing Hybridomas (%)	
			Exp. 1	Exp. 2
A	0.8	2.7	0	0
B	0.7	3.6	0	0
C	0.2	1.3	0	0
D	0.1	15.5	1	0
E	14.0	443.5	12	9
F	0.9	174.2	10	6
G	3.0	124.8	7	3
H	6.2	315.7	7	6

(Note)

1) The International Unit (IU/ml) were determined by AUSAB®.

2) Rate of Formation of Anti-HBsAg-Producing Hybridomas (%) = (The number of wells in which anti-HBsAg were produced / The total number of wells in which hybridomas are formed) x 100

Alternatively, hybridomas which effectively produce anti-HBsAg antibody can be derived from humans whose peripheral blood lymphocyte cells are cultured, after the vaccine administration, in vitro so that the culture supernatants exhibit high titers of anti-HBsAg. Thus, the

peripheral lymphocyte cells of the suppliers were collected, one week after the vaccine administration, and cultured in complete medium of RPMI 1640 + 15 % bovine fetal serum added with glutamine at 37 °C in the presence of 5 % CO₂ for seven days. The culture supernatants were determined with respect to titers of anti-HBsAg. The results are summarized in Table 2, which demonstrates that, for obtaining the hybridomas effectively producing anti-HBsAg antibody, the culture supernatants should have the titers of at least 0.01 IU/ml, most preferably at least about 0.1 IU/ml.

Table 2

Lympho- cyto Suppli- ers	Culture Supernatant Titer (IU/ml)		Rate of Formation of anti-HBsAg Producing Hybridomaa (%)	
	Before Immunization	One Week After Immunization	Exp. 1	Exp. 2
A	N D	N D	0	0
B	N D	N D	0	0
C	N D	N D	0	0
D	N D	0.01	1	0
E	N D	0.8	12	9
F	N D	0.3	10	6
G	N D	0.2	7	3
H	N D	0.8	7	6

(Note) N D : No Anti-HBsAg antibody was detected.

8. Effects of lymphocyte cells collection timing
and addition of pokeweed mitogen:

Fig. 1 illustrates the rate of formation of anti-HBsAg-producing hybridomas against time (one week, two weeks and three weeks) lapsed after the vaccine administration, with respect to some of the suppliers. As seen from Fig. 1, the lymphocyte cells collected two weeks after the vaccine administration will most efficiently form the desired hybridoma.

Fig. 1 also gives the results of the cases where PWM (pokeweed mitogen) were added prior to the cell fusions (shown in solid bars) and the cases where no PWM were added (shown in blank bars). It should be noted that, in the cases in which there present no bars in the graphs, no hybridomas were formed. The results demonstrate that addition of a lymphocyte activator such as PWM is very effective in forming the hybridoma.

9. Characterization of the hybridoma:

It was confirmed by means of conventional antibody-determining technique that the hybridoma according to the present invention when cultured in HAT medium produces anti-HBsAg antibody at the rate of $7 \mu\text{g}/5 \times 10^5$ cells/ml. The titer of the specific antibody is 2^{12} in terms of PHA as determined by hemagglutination method employing sheep red blood cells sensitized with HBsAg, and 50 in terms of IU/ml. These values substantially correspond to those found in humans having high titers of anti-HBsAg in

blood.

The anti-HBsAg monoclonal antibody prepared by the present invention does not react at all with anti-mouse immunoglobulin antiserum but reacts only with anti-human IgG antiserum, from which it is evidenced that the monoclonal antibody of the present invention belongs to the immunoglobulin class of human IgG.

The specificity of the monoclonal antibody of the present invention was determined by PHA-inhibition test employing sheep red blood cells sensitized with HBsAg, with the results as shown in Table 3.

Table 3

Monoclonal Antibody	HBsAg	adr	adw	ayw	Epitope recognized
Human MCA (the present invention)	>32	32	>32	>32	a
Mouse MCA HB7-2	>32	>32	>32	>32	a
Mouse MCA HB6-2	16	>32	< 2	< 2	a
Mouse MCA HB5-2	8	< 2	< 2	< 2	r

(Note) The numerical values in the table are dilution factors.

For comparison, the test was also conducted on some mouse monoclonal antibodies(MCA), the specificities of which were known in advance.

As a result, the hHBs MCA prepared according to the present invention reacted with all the subtypes, adr, adw, and ayw, of HBs antigen without causing hemagglutination. It was also found that the human anti-HBsAg monoclonal antibody of the present invention exhibited a reaction pattern quite similar to the pattern of the mouse MCA (designated HB7-2) which is known to recognize epitope "a" on HBs antigen. From these facts it was evidenced that the monoclonal antibody of the present will react with all the subtypes of hepatitis B surface antigen, suggesting that the monoclonal antibody of the invention is quite effective in preventing and treating the diseases due to the infection of hepatitis B virus.

Fig. 2 illustrates the results of the reaction of the human monoclonal antibody of the present invention, which has been bound onto HBsAg-sensitized polystyrene beads, with [¹²⁵I]-sheep-anti-human IgG or [¹²⁵I]-sheep-anti-mouse IgG. The results are also given with respect to a human anti-HBsAg polyclonal antibody (derived from human serum) and the mouse anti-HBsAg monoclonal antibody, as controls. In the graphs of Fig. 2, the abscissas designate dilution factors (in terms of x in 1/2^x) of the anti-HBs antibodies with the ordinates indicating cpm (counts per minute) as determined by the radioimmunoassay.

The human monoclonal antibody of the present invention does not react at all with [¹²⁵I]-sheep-anti-mouse IgG but reacts remarkably with [¹²⁵I]-sheep-anti-human IgG substantially linearly with the concentration of the antibody as seen from Fig. 2. The human anti-HBsAg polyclonal antibody derived from human serum exhibited a reaction pattern quite similar to that of the monoclonal antibody of the present invention while the mouse anti-HBsAg monoclonal antibody (HB7-2) exhibited a definitely different reaction pattern. From these facts, it is believed that the anti-HBsAg monoclonal antibody prepared by the present invention is a complete human antibody, not a human/mouse chimeric antibody.

Claims:

1. A method for preparing human-derived monoclonal antibodies to hepatitis B surface antigen (HBsAg) which comprises forming hybridomas by fusing peripheral blood lymphocyte cells which have been derived from humans having high titers of anti-HBsAg antibodies with myeloma cells, cloning the obtained hybridomas and selecting clones producing an antibody to the HBsAg.

2. The method according to claim 1, wherein the human for supplying the lymphocyte cells has a titer of anti-HBsAg antibodies of at least 10 IU/ml in blood.

3. The method according to claim 1, wherein the peripheral lymphocyte cells prior to the fusion are stimulated by the addition of a non-specific lymphocyte activator and cultured.

4. The method according to claim 1, wherein the myeloma cells are derived from mouse BALB/c myeloma cells, particularly P3-X63-Ag8-U1 or X-63-Ag8-6,5,3.

5. The method according to claim 1, wherein the hybridomas are propagated in vitro, particularly in a medium containing hypoxanthine-aminopterin-thymidine.

6. The method according to claim 1, wherein the hybridomas are propagated in an immunodeficient animal.








FIG. 1


4/2

0179483

(1) Human Anti-HBs Monoclonal Antibody



(3) Human Anti-HBs Polyclonal Antibody



(2) Mouse Anti-HBs Polyclonal Antibody




FIG. 2



Europäisches Patentamt
European Patent Office
Office européen des brevets

(11) Publication number:

0 179 483
A3

(12)

EUROPEAN PATENT APPLICATION

(21) Application number: 85113585.5

(51) Int. Cl.³: C 12 P 21/00
//A61K39/42, G01N33/577

(22) Date of filing: 25.10.85

(30) Priority: 26.10.84 JP 226394/84

(43) Date of publication of application:
30.04.86 Bulletin 86/18

(88) Date of deferred publication of search report: 01.03.89

(84) Designated Contracting States:
AT BE CH DE FR GB IT LI NL SE

(71) Applicant: Juridical Foundation The
Chemo-Sero-Therapeutic Research Institute
668, Ohkubo Shimizu-machi
Kumamoto-shi Kumamoto-ken(JP)

(72) Inventor: Eda, Yasuyuki
Yoshino-so 203 2-82, Shimizuhigashi-machi
Kumamoto-shi Kumamoto-ken(JP)

(72) Inventor: Maeda, Toshihiro
1909-1160, Kikutomi Koushi-machi
Kikuchi-gun Kumamoto-ken(JP)

(72) Inventor: Nishiyama, Kiyoto
Kei-Corpo 305, 923-1 Okubo, Shimizu-machi
Kumamoto-shi Kumamoto-ken(JP)

(72) Inventor: Tashiro, Akira
244-5, Suya Nishigoushi-machi
Kikuchi-gun Kumamoto-ken(JP)

(74) Representative: Vossius & Partner
Siebertstrasse 4 P.O. Box 86 07 67
D-8000 München 86(DE)

(54) Method for preparing monoclonal antibodies to HBsAg.

(57) Disclosed are monoclonal antibodies to the HBsAG which are prepared by forming hybridomas between human peripheral blood lymphocyte cells, derived from humans having high titers of anti-HBsAG antibodies, and myeloma cells, cloning the hybridomas and selecting the antibody-producing clones. The monoclonal antibodies react with all the subtypes of the HBsAG and are very effective in diagnosis and treatment of diseases due to the viral infection.

A3

EP 0 179 483



EUROPEAN SEARCH REPORT

EP 85 11 3585

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int. Cl.4)	
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl.4)	
Y	EP-A-0 027 657 (THE MASSACHUSETTS GENERAL HOSPITAL) * Whole document * ---	1,3-6	C 12 P 21/00 // A 61 K 39/42 G 01 N 33/577	
Y	J. EXP. MED., vol. 155, January 1982, pages 333-338, The Rockefeller University Press; H.C. LANE et al.: "Human monoclonal anti-keyhole limpet hemocyanin antibody-secreting hybridoma produced from peripheral blood B lymphocytes of a keyhole limpet hemocyanin-immune individual" * Whole article * ---	1,3-6		
Y	SCIENCE, vol. 210, 31st October 1980, pages 537-539, AAAS; R. NOWINSKI et al.: "Human monoclonal antibody against Forssman antigen" * Whole article * ---	1,3-5		
Y	EP-A-0 118 893 (SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH) * Pages 6-9: "Preparation of hybridomas"; claims 1,3-5 * ---	1,4,5		
X,P	BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 129, no. 1, 1985, 31st May 1985, pages 26-33, Academic Press, Inc.; Y. ICHIMORI et al.: "Establishment of hybridomas secreting human monoclonal antibodies against tetanus toxin and hepatitis B virus surface antigen" * Whole article * -----	1,3-5	A 61 K C 12 P	
The present search report has been drawn up for all claims			TECHNICAL FIELDS SEARCHED (Int. Cl.4)	
Place of search	Date of completion of the search	Examiner		
THE HAGUE	28-11-1988	CASTRO Y GONZALEZ R.F.		
CATEGORY OF CITED DOCUMENTS		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document		
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document		